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ABSTRAK 
Pencarian bio-penanda baru telah menjadi agenda utama aktiviti penyelidikan 
bagi penyakit Rheumatoid Arthritis (RA) pada dekad yang kebelakangan ini. Tujuan 
kajian ini adalah untuk menentukan korelasi serum matriks metalloproteinase-3 
(MMP-3) dengan aktiviti penyakit, kerosakan sendi dan ketidakupayaan pada 
pesakit dengan RA. Ini adalah satu kajian kes-kawalan keratan rentas yang 
melibatkan pesakit RA yang berada di bawah rawatan susulan di Pusat Perubatan 
Universiti Kebangsaan Malaysia (PPUKM). Maklumat mengenai ciri-ciri penyakit 
RA telah diperolehi daripada rekod perubatan dan semua pesakit RA telah dinilai 
untuk DAS28 (skor aktiviti penyakit berdasarkan 28 sendi) dan Stanford Penilaian 
Kesihatan Questionnaire (HAQ) 8-item Indeks Upaya (HAQ-DI). Radiograf tangan 
pesakit RA dinilai dengan menggunakan Skor Modified Sharp (MSS). Serum MMP-
3 dari pesakit RA dan kawalan yang sihat diukur dengan menggunakan kaedah 
ELISA. Seramai 77 pesakit RA dan 18 kawalan sihat telah mendaftar dalam kajian ini. 
Tahap serum MMP-3 adalah lebih tinggi di kalangan pesakit RA (p <0.05). Terdapat 
hubungan yang signifikan antara serum MMP-3 dan MSS (r = 0.327) dan HAQ-DI 
(r = 0.256), kedua-dua p <0.05. Tahap min serum MMP-3 pada pesakit RA dengan 
hakisan tulang radiografik adalah jauh lebih tinggi daripada pada pesakit tanpa 
hakisan (p <0.05). Tahap min MMP-3 di kalangan pesakit dengan ketidakupayaan 
yang signifikan iaitu HAQ-DI ≥1; jauh lebih tinggi berbanding pesakit RA tanpa 
kecacatan yang signifikan (p <0.05). Berdasarkan analisis multivariat, HAQ-DI 
kekal sebagai prediktor serum MMP-3 di kalangan pesakit RA. Serum MMP-3 
adalah penanda bio yang berpotensi meramalkan kerosakan sendi radiografik dan 
ketidakupayaan di kalangan pesakit RA.
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& Schett 2011). The consequent joint 
damage in RA often leads to deterioration 
in quality of life and severe functional 
impairment (Welsing et al. 2001).
 Despite the major advances in 
the treatment of RA with novel 
biologic therapies, there are still 
several unmet needs. These include 
reliable biomarkers which are able to 
accurately reflect the disease activity, 
prognosis and severity of the disease. 
Serum C-reactive protein (CRP) and 
Eryhtrocyte Sedimentation Rate 
Kata kunci: kecacatan sendi, matrix metalloproteinase-3, rheumatoid arthritis
ABSTRACT 
The search for novel biomarkers has taken centre stage in the past decades of 
research in Rheumatoid Arthritis (RA). The purpose of the present study was to 
determine the correlation of serum matrix metalloproteinase-3 (MMP-3) with 
disease activity, joint damage and functional disability in patients with RA. We 
consecutively recruited RA patients who were under follow-up at the Universiti 
Kebangsaan Malaysia Medical Centre (UKMMC). Information on the RA disease 
characteristics were obtained from the medical records and all RA patients were 
assessed for DAS28 (disease activity score based on 28 joints) and Stanford Health 
Assessment Questionnaire (HAQ) 8-item Disability Index (HAQ-DI). The hand 
radiographs of the RA patients were assessed for joint damage using the Modified 
Sharp Score (MSS).  Serum MMP-3 levels from RA patients and healthy controls 
were measured using the ELISA method. We recruited a total of 77 RA patients and 
18 healthy controls. The serum MMP-3 levels were significantly higher among the 
RA patients (p<0.05). There were significant correlations between the serum MMP-
3 levels and MSS (r =0.327) and HAQ-DI (r=0.256), both p<0.05. The mean serum 
MMP levels in RA patients with radiographic joint erosions was significantly higher 
than in patients without erosions (p<0.05). Likewise, the subjects with significant 
functional impairment i.e HAQ-DI ≥1; had significantly higher mean MMP-3 levels 
compared to RA patients without significant disability (p<0.05). Using multivariate 
analysis, HAQ-DI remained the independent predictor of serum MMP-3 in RA 
patients. Serum MMP-3 is a potential biomarker and predictor of radiographic joint 
damage and functional disability in RA.
Keywords: acquired joint deformity, matrix metalloproteinases, rheumatoid arthritis
INTRODUCTION
Rheumatoid Arthritis (RA) is the most 
common autoimmune inflammatory 
polyarthritis (Rothschild et al. 1988). It is 
characterized by synovial inflammation 
that may lead to irreversible destruction 
of the cartilage, tendons and bones. RA 
is also associated with autoantibody 
production (rheumatoid factor and anti–
citrullinated protein antibody (ACPA) 
with systemic features which may 
involve the cardiovascular, pulmonary 
and haematological systems (McInnes 
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(ESR) are the classical inflammatory 
biomarkers that are being used in the 
disease activity assessment of RA. 
Unfortunately, these biomarkers are 
non-specific and can be raised in 
many other inflammatory conditions 
eg infections and malignancies. A 
specific biomarker has a pivotal role 
in the management of RA to avoid 
undertreatment which leads to joint 
damage, or overtreatment which may 
pose unnecessary risks.
 Matrix metalloproteinase-3 (MMP-3) is 
a proteolytic enzyme and it is produced 
mainly by the chondrocytes and 
synovial fibroblasts. It has been found 
to be elevated in the serum and synovial 
fluid in patients with RA (Kobayashi et 
al. 2007; Mahmoud et al. 2005; Ribbens 
et al. 2002). Its production is upregulated 
by the proinflammatory cytokines IL-
1β, TNF, IFNγ, and IL-17A, as well as by 
serum amyloid A (SAA) in RA (Galliera, 
et al. 2010; Hueber et al. 2010). It also 
contributes to the progression of RA 
by promoting the recruitment of many 
other inflammatory cells ie neutrophils, 
monocytes and T cells (Jones et al. 2008). 
Since MMP-3 is produced in the inflamed 
joint, and subsequently circulated in the 
blood stream, it is a potential biomarker 
which may indicate the disease activity 
in RA (Zucker et al. 1994). In addition, 
elevated levels of MMP-3 may indicate 
ongoing destructive processes within 
the bones and synovium with resultant 
joint damage. The above however, is 
theoretical and has to be supported by 
clinical studies.
 Therefore, the main aim of the present 
study was to explore the correlation of 
serum MMP-3 with disease activity, joint 
damage and functional disability in RA.
MATERIALS AND METHODS
STUDY DESIGN AND STUDY 
POPULATION
This was an observational, case-control 
study involving RA patients who were 
under follow-up at the Universiti 
Kebangsaan Malaysia Medical Centre. 
This study was approved by the 
institutional review board and ethics 
committee (DLP 2013-039). The 
following were the inclusion criteria of 
this study; i) Patients diagnosed with 
RA based on American College of 
Rheumatology 1987 (Arnett et al. 1988) 
or 2010 (Aletaha et al. 2010), ii) Patients 
aged 18 yrs and above.
 The following patients were excluded: 
i) Patients who had previous hand and/
or wrist surgeries which may obscure 
the assessment of the hand radiographs, 
ii) Patients with active infections, iii) 
Patients with malignancies. 
 The subjects with RA were assessed 
for DAS28 (disease activity score based 
on 28 joints) and Stanford Health 
Assessment Questionnaire (HAQ)8-
item Disability Index (HAQ-DI). A 
total of 77 RA patients and 18 healthy 
controls consented and were tested 
for serum matrix metalloproteinase-3 
(MMP-3). The hand radiographs of 
the RA patients were scored using the 
Modified Sharp Score (MSS) by a single 
musculoskeletal radiologist who was 
blinded to the subjects. 
DATA COLLECTION
The medical records of all the subjects 
with RA were reviewed to gather 
information on the disease duration and 
seropositivity. The sociodemographic 
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data, Patient Global Assessment (PGA) 
scores and Stanford HAQ-DI scores 
were determined by questioning the 
subjects. The Stanford HAQ –DI 
consists of eight questions regarding the 
functional limitations in performing their 
activities of daily living. Patients were 
required to answer  on how difficult it 
was to perform an activity on a scale of 
0 (without any difficulty) to 3 (unable 
to do). The scores were averaged to 
a single total score (Fries et al. 1980). 
The Patient Global Assessment (PGA) 
required patients to state how they felt 
generally using a scale of 0 (very well) to 
10 (very poor) (Rohekar & Pope 2009). 
 In this study, the DAS 28 
calculation was performed by certified 
rheumatologists. The four parameters 
used to calculate  DAS 28 were; 
number of swollen joints, number of 
tender joints, C-reactive protein (CRP) 
or erythrocyte sedimentation rate (ESR), 
and the patient’s global assessment 
(Fransen & van Riel 2005; Prevoo et 
al. 1995). A DAS 28 of 3.2 and above 
(moderate to high disease activity) is 
considered as active disease. 
 Using the modified Sharp scoring 
(MSS) system (Pincus et al. 1997), 
each joint was scored for joint space 
narrowing and erosion. Fifteen sites in 
each hand and wrist were examined 
for joint space narrowing on a scale of 
0-4. Similarly, the erosions were scored 
individually at 16 sites in each hand 
and wrist.
SERUM MATRIX 
METALLOPROTEINASE-3(MMP-3)
Serum samples from all subjects were 
stored at −80˚C until analysis. Serum 
levels of soluble MMP-3 were measured 
with a human MMP-3 sandwich 
enzyme immunoassay detection kit 
(Quantikine, R&D systems) according 
to the manufacturer’s instructions. 
Measurements were done in duplicate. 
Serum samples were placed in 
designated microwells and both positive 
and negative calibrators were added to 
the designated microwells in order to 
determine a standard curve. The plates 
were then incubated for 30 mins at 26˚ C 
and washed with a buffer solution. 
STATISTICAL ANALYSIS
The statistical analyses were carried 
out using the Statistical Package for 
Social Sciences (SPSS) package for 
Windows version 21. Continuous 
variables were expressed as mean ±SD. 
Differences between the RA patients 
and healthy controls were analysed 
using the Chi-square test (categorical 
variables) and independent t-test 
(continuous variables). Correlations 
between the serum MMP-3 levels and 
clinical indicators were analysed by 
the Spearman’s rank order correlation 
test. A p value of <0.05 was considered 
statistically significant.
RESULTS
DEMOGRAPHIC DATA 
A total of 77 RA patients and 18 
healthy controls were enrolled in this 
study. The majority of the patients were 
females (89.6%). The subjects were 
predominantly Malays for both the 
RA patients (53.3%) and the controls 
(88.9%). The mean age of the subjects 
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with RA was 58.6 ±±10.3 yrs whereas 
for the controls was 56.4 ± 7.3 yrs. 
The demographic characteristics were 
matched between the RA patients and 
the controls (Table 1). The serum MMP-
3 levels were significantly higher among 
the RA patients (p<0.05). The mean 
serum MMP-3 level in RA patients was 
higher than the normal range (18–60 
ng/mL) whereas the healthy controls 
were within the range.  
CORRELATIONS BETWEEN SERUM 
MMP-3 LEVELS AND CLINICAL 
MEASURES OF DISEASE ACTIVITY, 
JOINT DAMAGE AND FUNCTIONAL 
DISABILITY
Spearman’s rank order correlation 
test showed significant correlations 
between the serum MMP-3 levels and 
MSS (r value of 0.327)  and HAQ-DI (r 
value of  0.256) (Table 2). The strength 
of the relationship however was only 
moderate for MSS (r within 0.3-0.5)  and 
weak for the HAQ-DI (r within 0.1-0.3). 
The mean serum MMP-3 levels in RA 
patients with radiographic joint erosions 
was significantly higher (p=0.017) than 
in patients without erosions (Figure 1). 
Likewise, the subjects with significant 
functional impairment i.e HAQ-DI ≥1; 
had significantly higher mean MMP-
3 levels (90.7 ng/ml) compared to RA 
patients without significant disability 
(80.3 ng/ml). There was no appreciable 
difference in this regard (p=0.268) 
between the active disease and 
inactive disease groups (Figure 1). Age 
and disease duration had an inverse 
relationship with the serum MMP-
3 levels. There were no significant 
correlations with the disease activity 
and inflammatory markers such as ESR 
and CRP (Table 2).
 A multiple regression analysis was 
performed to predict serum MMP-
3 from HAQ-DI, MSS, DAS 28, ESR 
and CRP. These variables statistically 
significantly predicted serum MMP-
3, F(5,95) = 7.368, p < 0.005, R2 = 
0.450. However, only HAQ-DI added 
significantly to the prediction, p<0.05.
Table 1: Clinical data of the RA patients and the controls
RA patients
(n = 77)
Controls
(n = 18) p-value
Age (years ) 58.6 ± 10.4 56.4 ± 7.3 0.398
Gender, n(%)  0.542
   Male 8 (10.4%) 1 (5.5%)
   Female 69 (89.6%) 17 (94.4%)
Ethnicity, n(%)  0.237
   Malay 42 (54.5%) 16 (88.9%)
   Chinese 20 (25.9%)     1 (5.5%)
   Indian  14 (18.2%) 1 (5.5%)
   Others 1 (1.2%) 0 (0%)
Serum MMP-3 82.73 ± 8.18 31.45 ± 3.29 <0.05
Data presented as either counts (percentages) or mean ± SD
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DISCUSSION
This study highlighted that serum MMP-
3 levels had a significant association 
with radiographic joint damage and 
functional impairment in RA. There is 
paucity of data on the predictive role of 
serum MMP-3 with regard to functional 
disability. However, a Japanese study 
(Shinozaki et al. 2007) reported that 
elevated serum MMP-3 predicted 
progressive disability based on JHAQ 
(Japanese version of HAQ) especially in 
female patients without corticosteroid. 
Galil et al. (2016), on the contrary, 
disclosed no positive correlations 
between serum MMP-3 levels and 
HAQ. Of note, the patients recruited by 
Galil et al. (2016) had joint symptoms 
for less than a year and hence, did not 
have significant functional disability. 
Our patients, on the other hand, had 
a mean disease duration of 10.5 yrs. 
We found that HAQ-DI was the only 
variable which significantly predicted 
serum MMP-3 using multiple regression 
analysis.
Table 2: Correlation analysis between serum MMP-3 levels and clinical parameters in 
RA
Variable Spearman’s rho p value
Age -0.041 0.734
Disease Duration -0.095 0.432
DAS 28 0.072 0.546
MSS 0.327 0.005
HAQ-DI 0.256 0.030
ESR 0.123 0.383
CRP 0.094 0.435
CRP; C reactive protein, ESR: erythrocyte sedimentation rate, HAQ-DI; Health Assessment 
Questionnaire Disability Index, MSS: Modified Sharp Score , DAS 28: 28 joint based Disease 
Activity Score 
Figure 1: Mean serum MMP-3 levels in the various groups of RA patients
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 The finding of significant positive 
correlation between radiographic joint 
damage and serum MMP-3 echoes the 
results of the previous studies in this 
regard (Cheung et al. 2000; Cunnane 
et al. 2001; Galil et al. 2016). Some of 
these studies could demonstrate the 
above link despite using a different 
joint scoring system i.e the Larsen 
score (Yamanaka et al. 2000). MMP-
3 acts directly on the matrix of the 
cartilage. In animal models, MMP-
3 was inducible and detectable in 
chondrocytes even in the early phase 
of arthritis (Okada et al. 1989; Singer 
et al. 1995).  Progressive degradation 
of the cartilage leads to joint space 
narrowing. Articular erosions are due to 
bone resorption which is facilitated by 
MMP-3-mediated removal of the outer 
osteoid layer (Cunnane et al. 2001) .
 In contrast to many previous studies 
(Ally et al. 2013; Galil et al. 2016; 
Ichikawa et al. 1998), we found no 
relationship between serum MMP-3 and 
either disease activity or inflammatory 
markers (ESR,CRP). The difference in the 
study population may partially explain 
our discrepant findings. We recruited 
all RA patients regardless of disease 
duration. Many of the studies which 
demonstrated a link between disease 
activity and MMP-3 included patients 
with only early disease (Urata et al. 
2012; Ally et al. 2013). The mean DAS 
28 in this study was 2.19 (in remission). 
In general, patients with early disease 
tend to have higher disease activity due 
to unoptimised treatment and while in 
the interim before the onset of action of 
disease modifying anti-rheumatic drugs.
 We do acknowledge the limitations 
of our study. As with most cytokines and 
biomarkers, MMP-3 levels may fluctuate 
in the blood circulation. Ideally, 2-3 
samples of blood should have been 
obtained from each subject on separate 
occasions. The average measurement 
of MMP-3 could have been used in 
the analysis. Each subject only had a 
single blood sample of MMP-3 taken; 
for convenience. Besides, ultrasound 
has been proven to be more sensitive in 
detecting joint erosions in RA. Early or 
mild erosions can be easily overlooked 
with plain radiographs (Filippucci et al. 
2006).
CONCLUSION
In conclusion, serum MMP-3 is a useful 
predictor of radiographic joint damage 
and functional disability in RA. The 
findings of this study have clinical 
implications. Novel therapies in RA 
should target MMP-3 to minimise joint 
destruction. Several models of MMP-3 
inhibitors are currently under phase I 
and II of clinical trials.
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